PRCT earnings analysis
What we found in PRCT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
PROCEPT BioRobotics recognized significant growth in Q1 2026, reporting revenues of $83.13 million, a 20% increase from $69.16 million in Q1 2025. Despite the growth in revenue, the company netted a loss of $31.64 million compared to a loss of $24.74 million in the previous year, primarily due to increased operating expenses for research and development as well as sales and administrative costs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Revenue Increase
- Revenue rose by 20% to $83.1 million compared to $69.2 million in Q1 2025.
- Improved Gross Margin
- Gross margin increased to 65% in Q1 2026 from 64% in Q1 2025.
- Increased System Sales
- System sales and leases grew by 21% to $27.24 million.
- Higher Consumables Revenue
- Handpieces and consumables revenue increased by 16% to $49.39 million.
- Operational Growth
- The total number of installed robotic systems reached 971, with a focus on increasing utilization and sales in the U.S.
- Strong Cash Position
- Cash and cash equivalents totaled $245.6 million as of March 31, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Rising Operating Loss
- Net loss increased by 28% to $31.64 million from $24.74 million in Q1 2025.
- Increased Operating Expenses
- Total operating expenses rose 21% to $86.55 million, driven by higher R&D and SG&A costs.
- Liquidity Concerns
- Despite a strong cash position, increased operational expenses may pressure future liquidity.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.56
- Gross margin
- 65%
What they said about what is next.
Management continues to anticipate annual revenue growth of 27% to 33% for 2026 compared to 2025.
The filing reads worse than the one before it.
What came before.
- 10-K · February 26, 2026
- PROCEPT reported full-year revenue of $308.1 million for the year ended December 31, 2025, up from $224.5 million in 2024, driven by system placements and disposables, but continued to incur losses (net loss $95.6…
- 10-K · February 27, 2025
- PROCEPT reported a strong revenue growth of 64.8% year-over-year, achieving $224.5 million in 2024, up from $136.2 million in 2023. However, the company is still incurring significant losses with a net loss of $91.4…
- 10-Q · October 28, 2024
- PROCEPT reported Q3 revenue of $58.37M (up from $35.10M in Q3 2023 and up vs Q2 2024 ~$53.35M), driving gross profit of $36.91M and a gross margin of 63.2%. Operating loss narrowed to $(22.43)M and diluted loss per…
- 10-Q · August 2, 2024
- PROCEPT reported strong top-line growth in Q2 with revenue of $53,353,000 (up from $33,104,000 in Q2 2023) and gross profit of $31,482,000, driving a gross margin of 59.0%. Despite revenue and margin improvement,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PRCT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever